Comparative Pharmacology
Head-to-head clinical analysis: AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE versus NAQUA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE versus NAQUA.
AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE vs NAQUA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amiloride is a potassium-sparing diuretic that blocks epithelial sodium channels (ENaC) in the distal convoluted tubule and collecting duct, inhibiting sodium reabsorption and reducing potassium excretion. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride cotransporter (NCC) in the distal convoluted tubule, increasing sodium, chloride, and water excretion.
Inhibition of sodium-chloride symporter (NCC) in the distal convoluted tubule of the kidney, reducing sodium and chloride reabsorption and promoting diuresis.
One tablet (amiloride 5 mg/hydrochlorothiazide 50 mg) orally once daily initially, increased if needed to twice daily. Maximum dose: amiloride 10 mg/hydrochlorothiazide 100 mg daily.
Oral: 5-10 mg once daily, preferably in the morning. Maximum dose 20 mg/day.
None Documented
None Documented
Amiloride: 6-9 hours (prolonged in renal impairment); Hydrochlorothiazide: 6-15 hours (prolonged in renal impairment, heart failure).
Terminal elimination half-life is 6-12 hours; prolonged in renal impairment (up to 20-30 hours) or heart failure due to reduced renal perfusion.
Amiloride: 50% unchanged in urine, 40% in feces (biliary); Hydrochlorothiazide: >95% unchanged in urine.
Primarily renal elimination; approximately 60-80% excreted unchanged in urine via tubular secretion; minor biliary/fecal excretion (<10%).
Category A/B
Category C
Thiazide Diuretic
Thiazide Diuretic